SAGE News and Press, Sage Therapeutics Inc. From 02/14/24

2024-02-14 13:00:04 ET SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Conference Call February 14, 2024, 8:00 a.m. ET Company Participants Barry Greene - President, CEO & Director Kimi Iguchi - CFO & Treasurer Laura Gault - Chief Medical Officer Chri...

2024-02-14 06:33:52 ET More on Sage Therapeutics Sizing Up Sage Therapeutics Biogen, Sage launch depression therapy in the U.S. Seeking Alpha’s Quant Rating on Sage Therapeutics Historical earnings data for Sage Therapeutics Financial informati...

ZURZUVAE™ (zuranolone), the first-and-only oral treatment indicated for adults with postpartum depression (PPD), became commercially available mid-December; Sage achieved $0.8 million in collaboration revenue as of December 31, 2023, 50% of the net revenues Biogen reports for ZURZUVAE ...

Owens Corning Inc New (OC) is expected to report $2.82 for Q4 2023 Getty Realty Corporation (GTY) is expected to report $0.56 for Q4 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q2 2024 Nexien BioPharma Inc (NXEN) is expected to report for Q2 2024 Ayt...

2024-02-13 11:09:44 ET More on Sage Therapeutics Sizing Up Sage Therapeutics Biogen, Sage launch depression therapy in the U.S. Seeking Alpha’s Quant Rating on Sage Therapeutics Historical earnings data for Sage Therapeutics Financial informati...

2024-02-13 07:59:24 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen misses top-line and bottom-line estimates; initiates FY...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discus...

2024-01-22 13:17:30 ET Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. Th...

2024-01-11 06:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Excitement over December 2023 launch of ZURZUVAE™ (zuranolone), the first and only oral treatment indicated for adults with postpartum depression (PPD) Continued progress on clinical pipeline, with topline data expected from multiple ongoing Phase 2 trials across 2024 ...